NeuroOne Medical Technologies Corporation develops medical technology for surgical diagnosis and treatment of neurological disorders. The company’s platform centers on thin-film electrode technology used in recording, monitoring, mapping, ablation and brain stimulation applications, including Evo Cortical, Evo sEEG and the OneRF Ablation System.
NeuroOne news commonly covers FDA 510(k) clearances, product applications for epilepsy, facial pain and other neurosurgical uses, patent activity around neural probe and electrode technologies, financial results, capital raises, commercial orders, investor conferences and management updates. Coverage also reflects the company’s efforts to extend the OneRF platform into additional ablation, stimulation and drug-delivery applications.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC), a medical technology company specializing in neurological disorder surgical care solutions, has announced its participation in the upcoming MedInvest MedTech, AI and Digital Health Conference. The event will take place on June 3-4, 2025, at the O'Melveny Conference Center in San Francisco, CA.
Dave Rosa, President and CEO of NeuroOne, will be conducting investor meetings during this two-day conference, which will feature panel discussions, keynote talks, and corporate presentations focusing on medical devices, imaging technologies, diagnostics, AI/data analytics, and digital health. The MedInvest Conference is recognized as a leading conference series in Healthcare and Life Sciences, hosting semiannual events in Biotech, Pharma, MedTech, AI, and Digital Health sectors.
NeuroOne Medical Technologies (NASDAQ: NMTC) reported strong Q2 FY2025 financial results, with significant gross margin improvement to 55.6% from 28.3% YoY. Product revenue remained stable at $1.4M for Q2, while H1 FY2025 product revenue grew 98% to $4.7M. The company successfully filed an FDA submission for its OneRF® Trigeminal Nerve Ablation System ahead of schedule and completed an oversubscribed $8.2M capital raise in April 2025.
The company reaffirmed its FY2025 product revenue guidance of $8.0-10.0M, representing 132-190% growth YoY. NeuroOne strengthened its management team with key appointments and remains debt-free, with funding secured through FY2026. The first patient treated with OneRF Ablation System will reach one year of seizure freedom in June 2025, marking a significant milestone for the company's technology.
NeuroOne Medical Technologies (NASDAQ: NMTC) has appointed Dr. Parag G. Patil as Chief Medical Advisor (CMA), upgrading his role from the company's Scientific Advisory Board where he has served since 2018. Dr. Patil, a neurosurgeon-engineer with 20 years of experience, is currently an Associate Professor at the University of Michigan in multiple departments and serves as Associate Chair for Clinical and Translational Research.
Dr. Patil's expertise spans electrophysiology, imaging, and mathematical modeling, with a focus on developing improved therapies for paralysis, pain, and movement disorders using neural-interface devices. In his new role, he will assist with NeuroOne's clinical strategy, product development, physician education, and professional society partnerships while maintaining his faculty position.
NeuroOne Medical (NASDAQ: NMTC) has announced its participation in the upcoming D. Boral Capital Inaugural Global Conference. The event will take place on May 14, 2025, at The Plaza Hotel in New York City. The company's CFO, Ron McClurg, will be available for one-on-one meetings from 9:00 A.M. to 3:00 P.M. (ET). Interested parties can schedule meetings by contacting John Perez at jperez@dboralcapital.com.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC), a medical technology company specializing in neurological disorder treatments, will announce its fiscal second quarter 2025 financial results on May 13, 2025, before market open. The company will host an investor conference call and webcast at 8:30 a.m. Eastern time the same day.
Management will discuss Q2 financial results, provide corporate updates, and hold a Q&A session. The conference call can be accessed via U.S. toll-free number (888-506-0062) or international number (973-528-0011) using participant code 655933. A playback will be available until May 27, 2025, through domestic (877-481-4010) and international (919-882-2331) numbers with replay passcode 52404.
NeuroOne Medical Technologies (Nasdaq: NMTC) has submitted a 510(k) application to the FDA for its OneRF® Trigeminal Nerve Ablation System, ahead of schedule. The system aims to treat trigeminal neuralgia, a chronic facial pain condition affecting approximately 100,000 Americans.
The technology features a minimally invasive surgical procedure using radiofrequency energy to destroy abnormal tissue. Key features include multi-point mapping of pain location, stimulation, and temperature-controlled ablation, all using the same electrode. Published data indicates RF ablation achieves ~95% initial pain relief rates with long-term efficacy and low complication rates.
If FDA cleared, NeuroOne anticipates potential revenue generation from trigeminal nerve ablation by late 2025. The system builds upon the company's FDA-cleared OneRF sEEG Ablation System for brain procedures.
NeuroOne Medical Technologies (NMTC) has issued a shareholder letter highlighting recent achievements and future outlook. The company expanded its partnership with Zimmer Biomet, securing exclusive distribution rights for the OneRF® Ablation System with a $3.0 million upfront payment in November 2024.
The company recently raised $8.3 million from institutional investors, ensuring funding through fiscal 2026. NeuroOne confirmed no material impact from global tariffs due to its US-based supply chain. They plan to submit a 510(k) filing to FDA in May 2025 for trigeminal nerve ablation treatment.
For fiscal year 2025, NeuroOne projects product revenues of $8.0-$10.0 million (132%-190% increase from $3.5 million in FY2024) and improved gross margins of 47%-51% (up from 31% in FY2024). The company is also advancing its Spinal Cord Stimulation Program and sEEG-Based Drug Delivery Program, with strategic partnership discussions underway.
NeuroOne Medical Technologies (Nasdaq: NMTC) announced that its OneRF® Ablation System was featured in a national Fox News article highlighting a successful pediatric epilepsy treatment. The article showcases 17-year-old Clara Fuller, who previously experienced up to 10 seizures nightly due to a rare, medication-resistant epilepsy.
Clara made history as the first pediatric patient treated with NeuroOne's OneRF® technology, which performs minimally invasive radiofrequency ablation of seizure-causing brain tissue. Following the procedure, Clara has become completely seizure-free, enabling her to sleep uninterrupted and resume normal teenage activities.
NeuroOne Medical Technologies (NMTC) has announced the pricing of an underwritten public offering of 16,000,000 shares of common stock at $0.50 per share, aiming to raise $8.0 million in gross proceeds.
The company has granted the underwriter, Ladenburg Thalmann & Co. Inc., a 45-day option to purchase up to an additional 2,400,000 shares at the public offering price less underwriting discount. The offering is expected to close around April 7, 2025.
The net proceeds will be used for general working capital purposes. The shares will be issued under a shelf registration statement on Form S-3 that was declared effective by the SEC on August 16, 2024.
NeuroOne Medical Technologies (NMTC), a medical technology company focused on neurological disorder surgical care, has announced a proposed underwritten registered public offering of common stock shares. The company plans to grant the underwriter a 45-day option to purchase up to an additional 15% of the offered shares.
Ladenburg Thalmann & Co. Inc. will serve as the sole book-running manager for this offering, which will be conducted under an effective shelf registration statement on Form S-3. The offering's completion, size, and terms are subject to market conditions, with no guarantees of successful execution.
The shares will be available through a preliminary prospectus supplement and accompanying prospectus to be filed with the SEC. The offering will only proceed in jurisdictions where it complies with securities laws and registration requirements.